Immunogenicity of somatic mutations in human gastrointestinal cancers
- PMID: 26516200
- PMCID: PMC7445892
- DOI: 10.1126/science.aad1253
Immunogenicity of somatic mutations in human gastrointestinal cancers
Abstract
It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TILs) from 9 out of 10 patients with metastatic gastrointestinal cancers contained CD4(+) and/or CD8(+) T cells that recognized one to three neo-epitopes derived from somatic mutations expressed by the patient's own tumor. There were no immunogenic epitopes shared between these patients. However, we identified in one patient a human leukocyte antigen-C*08:02-restricted T cell receptor from CD8(+) TILs that targeted the KRAS(G12D) hotspot driver mutation found in many human cancers. Thus, a high frequency of patients with common gastrointestinal cancers harbor immunogenic mutations that can potentially be exploited for the development of highly personalized immunotherapies.
Copyright © 2015, American Association for the Advancement of Science.
Figures
Similar articles
-
Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.Cell Immunol. 1997 Dec 15;182(2):137-51. doi: 10.1006/cimm.1997.1224. Cell Immunol. 1997. PMID: 9514698 Clinical Trial.
-
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.Clin Cancer Res. 2014 Jan 15;20(2):331-43. doi: 10.1158/1078-0432.CCR-13-1736. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218514 Free PMC article.
-
High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12826-12835. doi: 10.1073/pnas.1921964117. Epub 2020 May 27. Proc Natl Acad Sci U S A. 2020. PMID: 32461371 Free PMC article.
-
Mutant ras epitopes as targets for cancer vaccines.Semin Oncol. 1996 Feb;23(1):118-34. Semin Oncol. 1996. PMID: 8607022 Review.
-
Personalized vaccines for cancer immunotherapy.Science. 2018 Mar 23;359(6382):1355-1360. doi: 10.1126/science.aar7112. Science. 2018. PMID: 29567706 Review.
Cited by
-
Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes.Sci Adv. 2024 Sep 20;10(38):eado6491. doi: 10.1126/sciadv.ado6491. Epub 2024 Sep 18. Sci Adv. 2024. PMID: 39292790 Free PMC article.
-
Recent clinical researches and technological development in TIL therapy.Cancer Immunol Immunother. 2024 Sep 12;73(11):232. doi: 10.1007/s00262-024-03793-4. Cancer Immunol Immunother. 2024. PMID: 39264449 Free PMC article. Review.
-
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.J Immunother Cancer. 2024 Sep 6;12(9):e008516. doi: 10.1136/jitc-2023-008516. J Immunother Cancer. 2024. PMID: 39244214 Free PMC article.
-
Influenza vaccination stimulates maturation of the human T follicular helper cell response.Nat Immunol. 2024 Sep;25(9):1742-1753. doi: 10.1038/s41590-024-01926-6. Epub 2024 Aug 20. Nat Immunol. 2024. PMID: 39164477 Free PMC article.
-
T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.Mol Ther. 2024 Sep 4;32(9):2856-2891. doi: 10.1016/j.ymthe.2024.07.028. Epub 2024 Aug 5. Mol Ther. 2024. PMID: 39095991 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous